SCHAUMBURG, Illinois — Injectables manufacturer Sagent Pharmaceuticals -- fresh off $30 million investment — has added a $15 million revolving credit facility. The company said only the funding would be used to fund “increasing working capital requirements” and other general purposes.
The revolving credit is through MidCap Financial LLC.
“This facility provides Sagent with non-dilutive capital and additional liquidity to support the company’s significant upcoming product introductions and accelerated growth,” Ronald E. Pauli, Sagent’s chief financial officer, stated in a release.
Sagent in May added $30 million to its Series A round (bringing it to $113 million) to help launch a series of new products. It has about 10 products on the market and said recent said it expected to have 20 products launched by year’s end.
Targeted drug hopes to have success attacking multiple cancers
New drugs for epilepsy, pain are focus of NeuroTherapeutics’ $47.5M round
Hospira class actions claim company failed to disclose problems at N.C. plant
Hospira commits $375M to make troubled N.C. plant FDA compliant
Sign up for MedCity News' e-newsletter, providing medical industry news from across the country.
Sign up
Anyone can blog on MedCity News when they become a "MedCitizen." MedCitizens publish their own thoughts about current medical news and the latest issues in healthcare to the entire MedCity News audience.
Amy SiegelHow low can you go? Creating value with cheap medical devices
Steven M. Auvil (Sponsored)5 things med tech companies need to know about the Leahy-Smith America Invents Act
Jim TateEscape Hatch for Electronic Submission of CQMs for Meaningful Use
Lisa Suennen2012 JP Morgan Healthcare’s (wo)men’s club is changing in a good way
Joe HageA huge American opportunity waiting to happen
Doug MowenMed tech consolidation brings a need for focus. Here are 2 ways to get it
Comments
Post a comment
No comments yet.
Post a Comment